Drugs.com - Clinical Trials

Results From Amgen's Phase 2 Obesity Study of Monthly MariTide Presented at the American Diabetes Association 85th Scientific Sessions

THOUSAND OAKS, Calif., June 23, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously...

Jun 24, 2025 - 01:45
 0
Results From Amgen's Phase 2 Obesity Study of Monthly MariTide Presented at the American Diabetes Association 85th Scientific Sessions
THOUSAND OAKS, Calif., June 23, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously...
Read More

Tags:

Previous Article

Repérées sur VivaTech : trois innovations qui transforment l'expérience client

Next Article

Datroway Approved in the U.S. as First TROP2 Directed Therapy for Patients with ...

Related Posts

Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia

Axsome Therapeutics Provides Update on the New Drug App...

Jun 10, 2025  0

Rilzabrutinib Granted Orphan Drug Designation in the US for Sickle Cell Disease

Rilzabrutinib Granted Orphan Drug Designation in the US...

Jun 3, 2025  0

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

BeiGene Provides Update on the Ociperlimab (BGB-A1217) ...

May 12, 2025  0